’s Mounjaro, a diabetes drug that the company is hoping will be approved for obesity later this year, experienced continued weight loss in a trial that showed the drug’s effects don’t slow over time.
Those who stayed on the drug for the duration of the 88-week study lost about 26% of their body weight, or 61.5 pounds, Lilly
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more: